Tonatiuh Abimael Baltazar-Díaz

Dr. Tonatiuh Abimael Baltazar-Díaz

Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
Tonatiuh Abimael Baltazar-DíazTonatiuh Abimael Baltazar-Díaz
Tonatiuh Abimael Baltazar-Díaz
LGLuz Alicia González-Hernández
Luz Alicia González-Hernández
JAJuan Manuel Aldana-Ledesma
Juan Manuel Aldana-Ledesma
MRMarcela Peña Rodríguez
Marcela Peña Rodríguez
Natali Vega-MagañaNatali Vega-Magaña
Natali Vega-Magaña
MBMiriam Ruth Bueno
Miriam Ruth Bueno
Gut microbiota undergoes profound alterations in alcohol cirrhosis. Microbiota-derived products, e.g., short chain fatty acids (SCFA), regulate the homeostasis of the gut-liver axis. The objective was to evaluate the composition and functions of the intestinal microbiota in patients with alcohol-decompensated cirrhosis. Fecal samples of 18 patients and 18 healthy controls (HC) were obtained. Microbial composition was characterized by 16S rRNA amplicon sequencing, SCFA quantification was performed by gas chromatography (GC), and metagenomic predictive profiles were analyzed by PICRUSt2. Gut microbiota in the cirrhosis group revealed a significant increase in the pathogenic/pathobionts genera Escherichia/Shigella and Prevotella, a decrease in beneficial bacteria, such as Blautia, Faecalibacterium, and a decreased α-diversity (p < 0.001) compared to HC. Fecal SCFA concentrations were significantly reduced in the cirrhosis group (p < 0.001). PICRUSt2 analysis indicated a decrease in acetyl-CoA fermentation to butyrate, as well as an increase in pathways related to antibiotics resistance, and aromatic amino acid biosynthesis. These metabolic pathways have been poorly described in the progression of alcohol-related decompensated cirrhosis. The gut microbiota of these patients possesses a pathogenic/inflammatory environment; therefore, future strategies to balance intestinal dysbiosis should be implemented. These findings are described for the first time in the population of western Mexico.

6 April 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
Tonatiuh Abimael Baltazar-DíazTonatiuh Abimael Baltazar-Díaz
Tonatiuh Abimael Baltazar-Díaz
FAFernando Universitario Amador-Lara
Fernando Universitario Amador-Lara
JAJaime F. Andrade-Villanueva
Jaime F. Andrade-Villanueva
LGLuz Alicia González-Hernández
Luz Alicia González-Hernández
RSRodolfo Ismael Cabrera Silva
Rodolfo Ismael Cabrera Silva
MBMiriam Ruth Bueno
Miriam Ruth Bueno
Antiretroviral therapies (ART) are strongly associated with weight gain and metabolic syndrome (MetS) development in HIV-infected patients. Few studies have evaluated the association between gut microbiota and integrase strand transfer inhibitor (INSTI)-based and protease inhibitor (PI)-based regimens in HIV-infected patients with MetS. To assess this, fecal samples were obtained from HIV-infected patients treated with different regimens (16 PI + MetS or 30 INSTI + MetS) and 18 healthy controls (HCs). The microbial composition was characterized using 16S rRNA amplicon sequencing. The INSTI-based and PI-based regimens were associated with a significant decrease in α-diversity compared to HCs. The INSTI + MetS group showed the lowest α-diversity between both regimens. A significant increase in the abundance of short-chain fatty acid (SCFA)-producing genera (Roseburia, Dorea, Ruminococcus torques, and Coprococcus) was observed in the PI + MetS group, while Prevotella, Fusobacterium, and Succinivibrio were significantly increased in the INSTI + MetS group. Moreover, the Proteobacteria/Firmicutes ratio was overrepresented, and functional pathways related to the biosynthesis of LPS components were increased in the INSTI + MetS group. The gut microbiota of patients receiving INSTIs showed a more pronounced dysbiosis orchestrated by decreased bacterial richness and diversity, with an almost complete absence of SCFA-producing bacteria and alterations in gut microbiota functional pathways. These findings have not been previously observed.

11 February 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
VRVerónica Riggen-Bueno
Verónica Riggen-Bueno
STSusana del Toro-Arreola
Susana del Toro-Arreola
Tonatiuh Abimael Baltazar-DíazTonatiuh Abimael Baltazar-Díaz
Tonatiuh Abimael Baltazar-Díaz
Natali Vega-MagañaNatali Vega-Magaña
Natali Vega-Magaña
MRMarcela Peña Rodríguez
Marcela Peña Rodríguez
MBMiriam Ruth Bueno
Miriam Ruth Bueno
Obesity is a public health problem with a growing prevalence worldwide. In Mexico, it is estimated that one out of three adults suffer from obesity. In these patients, the intestinal microbiota (IM) undergoes pathological changes that are associated with a dysbiotic state; however, the microbiota profile of adult subjects with obesity from western Mexico has not been described. To assess this, fecal samples were obtained from 65 participants (Obese = 38; Control = 27). The microbial composition was characterized by 16S rRNA amplicon sequencing. The IM of the group with obesity revealed a clear decrease in richness and diversity (p < 0.001), as well as a significant increase in proinflammatory bacterial groups, mainly genera belonging to the Negativicutes class, Escherichia/Shigella, and Prevotella. Likewise, an increase in short-chain fatty acid-producing bacteria was found, especially the genus Lachnoclostridium. Additionally, PICRUSt2 analysis showed a depletion of vitamin B9 metabolism and an increase in saccharolytic pathways. The IM of patients with obesity possesses a dysbiotic, proinflammatory environment, possibly contributing to lipogenesis and adiposity. Thus, assessing the IM will allow for a better understanding of the pathophysiology of metabolic diseases of high prevalence, such as obesity. These findings are described for the first time in the adult population of western Mexico.

Verified
Journal Article
Open access
PDF file
Tonatiuh Abimael Baltazar-DíazTonatiuh Abimael Baltazar-Díaz
Tonatiuh Abimael Baltazar-Díaz
JAJaime F. Andrade-Villanueva
Jaime F. Andrade-Villanueva
PAPaulina Alejandra Sánchez Alvarez
Paulina Alejandra Sánchez Alvarez
FAFernando Universitario Amador-Lara
Fernando Universitario Amador-Lara
THTania Elisa Holguin
Tania Elisa Holguin
LGLuz Alicia González-Hernández
Luz Alicia González-Hernández
HIV infection results in marked alterations in the gut microbiota (GM), such as the loss of microbial diversity and different taxonomic and metabolic profiles. Despite antiretroviral therapy (ART) partially ablating gastrointestinal alterations, the taxonomic profile after successful new ART has shown wide variations. Our objective was to determine the GM composition and functions in people living with HIV (PLWHIV) under ART in comparison to seronegative controls (SC). Fecal samples from 21 subjects (treated with integrase strand-transfer inhibitors, INSTIs) and 18 SC were included. We employed 16S rRNA amplicon sequencing, coupled with PICRUSt2 and fecal short-chain fatty acid (SCFA) quantification by gas chromatography. The INSTI group showed a decreased α-diversity (p < 0.001) compared to the SC group, at the expense of increased amounts of Pseudomonadota (Proteobacteria), Segatella copri, Lactobacillus, and Gram-negative bacteria. Concurrently, we observed an enrichment in Megasphaera and Butyricicoccus, both SCFA-producing bacteria, and significant elevations in fecal butyrate in this group (p < 0.001). Interestingly, gut dysbiosis in PLWHIV was characterized by a proinflammatory environment orchestrated by Pseudomonadota and elevated levels of butyrate associated with bacterial metabolic pathways, as well as the evident presence of butyrogenic bacteria. The role of this unique GM in PLWHIV should be evaluated, as well as the use of butyrate-based supplements and ART regimens that contain succinate, such as tenofovir disoproxil succinate. This mixed profile is described for the first time in PLWHIV from Mexico.

Verified
Journal Article
Open access
PDF file
Elia Ana Baltazar GarcíaElia Ana Baltazar García
Elia Ana Baltazar García
BVBelinda Vargas-Guerrero
Belinda Vargas-Guerrero
ALAna Lima
Ana Lima
RFRicardo Boavida Ferreira
Ricardo Boavida Ferreira
MMMaría Luisa Mendoza-Magaña
María Luisa Mendoza-Magaña
CGCarmen Magdalena Gurrola-Díaz
Carmen Magdalena Gurrola-Díaz
Chronic obstructive pulmonary disease (COPD) is comprised of histopathological alterations such as pulmonary emphysema and peribronchial fibrosis. Matrix metalloproteinase 9 (MMP-9) is one of the key enzymes involved in both types of tissue remodeling during the development of lung damage. In recent studies, it was demonstrated that deflamin, a protein component extracted from Lupinus albus, markedly inhibits the catalytic activity of MMP-9 in experimental models of colon adenocarcinoma and ulcerative colitis. Therefore, in the present study, we investigated for the first time the biological effect of deflamin in a murine COPD model induced by chronic exposure to ozone. Ozone exposure was carried out in C57BL/6 mice twice a week for six weeks for 3 h each time, and the treated group was orally administered deflamin (20 mg/kg body weight) after each ozone exposure. The histological results showed that deflamin attenuated pulmonary emphysema and peribronchial fibrosis, as evidenced by H&E and Masson’s trichrome staining. Furthermore, deflamin administration significantly decreased MMP-9 activity, as assessed by fluorogenic substrate assay and gelatin zymography. Interestingly, bioinformatic analysis reveals a plausible interaction between deflamin and MMP-9. Collectively, our findings demonstrate the therapeutic potential of deflamin in a COPD murine model, and suggest that the attenuation of the development of lung tissue damage occurs by deflamin-regulated MMP-9 catalytic activity.

15 May 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
PJPaula Alejandra Castaño Jimenez
Paula Alejandra Castaño Jimenez
Tonatiuh Abimael Baltazar-DíazTonatiuh Abimael Baltazar-Díaz
Tonatiuh Abimael Baltazar-Díaz
LGLuz Alicia González-Hernández
Luz Alicia González-Hernández
Roxana García-SalcidoRoxana García-Salcido
Roxana García-Salcido
KKKsenia Klimov-Kravtchenko
Ksenia Klimov-Kravtchenko
MBMiriam Ruth Bueno
Miriam Ruth Bueno
ACLF is a severe stage of liver cirrhosis, characterized by multiple organ failure, systemic inflammation, and high short-term mortality. The intestinal microbiota (IM) influences its pathophysiology; however, there are currently no studies in Latin American populations. Therefore, we analyzed IM and its relationships with sepsis, organ failure, and mortality. In parallel, we quantified serum lipopolysaccharides as a marker of bacterial translocation. Fecal samples from 33 patients and 20 healthy controls (HCs) were obtained. The IMs were characterized by 16S-rRNA amplicon sequencing, the metagenomic functional predictive profiles were analyzed by PICRUSt2, and LPS quantification was performed by ELISA. Patients with ACLF showed significant alterations in alpha and beta diversity compared to the HCs. A strong dominance index accurately predicted 28-day and 90-day mortalities. The IMs showed a polarization toward Proteobacteria associated with increased LPS. The LPS correlated with clinical severity, organ dysfunction, and higher pathogenic taxa. The Klebsiella/Faecalibacterium ratio showed good performance in identifying sepsis (AUROC = 0.83). Furthermore, Morganella, Proteus, and Klebsiella were enriched in patients with multiorgan failure. Lactobacillus, Escherichia/Shigella, Veillonella, and Ruminococcus gnavus exhibited potential in predicting 28- and 90-day mortalities. The IM alterations in ACLF may be useful as clinical biomarkers of poor prognosis, primarily for mortality and sepsis. These findings are representative of western Mexico.